
Creyon Bio offers Creyon Preclinical RNA Therapy Pipeline
Wholly-owned preclinical RNA therapy pipeline across immunology, CNS, and neuromuscular disease.
- Currently Offered

Wholly-owned preclinical RNA therapy pipeline across immunology, CNS, and neuromuscular disease.
Creyon advances three active wholly-owned preclinical RNA therapy programs: aptamer-mediated oligonucleotide and lipid nanoparticle delivery to activated immune cells in immunology; transferrin receptor aptamer delivery of siRNA and antisense oligonucleotides across the blood-brain barrier in central nervous system disease; and an aptamer-ASO conjugate including a first-in-class splice-switching oligonucleotide for late-onset Pompe disease in neuromuscular disease.
Programs are preclinical with a first clinical entry guided for the near term, including a lead neuromuscular candidate targeted for the clinic in 2026.


Antisense oligonucleotide portfolio for neurological disease including spinal muscular atrophy and ALS.


RNA-targeted medicines pipeline spanning neurology, cardiology, and rare disease programs.


RNA exon-skipping and gene therapy portfolio for Duchenne muscular dystrophy and rare neuromuscular disease.
Antisense oligonucleotide portfolio for neurological disease including spinal muscular atrophy and ALS.

RNA-targeted medicines pipeline spanning neurology, cardiology, and rare disease programs.

RNA exon-skipping and gene therapy portfolio for Duchenne muscular dystrophy and rare neuromuscular disease.



Biomolecular RNA delivery platform targeting specific cells and organs including across the blood-brain barrier.


Med-Oligo is AusperBio's antisense oligonucleotide design platform using positioned chemical modifications for higher potency.
Biomolecular RNA delivery platform targeting specific cells and organs including across the blood-brain barrier.

Med-Oligo is AusperBio's antisense oligonucleotide design platform using positioned chemical modifications for higher potency.
